Last reviewed · How we verify
Usual Antipsychotic Treatment
Usual Antipsychotic Treatment is a Small molecule drug developed by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla. It is currently in Phase 2 development. Also known as: TAU.
At a glance
| Generic name | Usual Antipsychotic Treatment |
|---|---|
| Also known as | TAU |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Weight Gain
- Hyperprolactemia
- Elevated cholesterol levels
- Hepatic enzyme abnormalities
- Depression
- Hypertension
- Insomnia
- Anxiety
- Tachycardia
- Somnolence
- Hostility/aggression
- Restlessness
Key clinical trials
- Cue-based Intervention in Prospective Memory and Medication Adherence. (NA)
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia (NA)
- Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis (NA)
- Strategic Timing of Resistance Training to Guard Against Antipsychotic-Induced Metabolic Syndrome (NA)
- Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial (NA)
- Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial (PHASE4)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Usual Antipsychotic Treatment CI brief — competitive landscape report
- Usual Antipsychotic Treatment updates RSS · CI watch RSS
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla portfolio CI
Frequently asked questions about Usual Antipsychotic Treatment
What is Usual Antipsychotic Treatment?
Usual Antipsychotic Treatment is a Small molecule drug developed by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla.
Who makes Usual Antipsychotic Treatment?
Usual Antipsychotic Treatment is developed by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (see full Fundación Pública Andaluza para la gestión de la Investigación en Sevilla pipeline at /company/fundaci-n-p-blica-andaluza-para-la-gesti-n-de-la-investigaci-n-en-sevilla).
Is Usual Antipsychotic Treatment also known as anything else?
Usual Antipsychotic Treatment is also known as TAU.
What development phase is Usual Antipsychotic Treatment in?
Usual Antipsychotic Treatment is in Phase 2.
What are the side effects of Usual Antipsychotic Treatment?
Common side effects of Usual Antipsychotic Treatment include Weight Gain, Hyperprolactemia, Elevated cholesterol levels, Hepatic enzyme abnormalities, Depression, Hypertension.
Related
- Manufacturer: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full pipeline
- Also known as: TAU
- Compare: Usual Antipsychotic Treatment vs similar drugs
- Pricing: Usual Antipsychotic Treatment cost, discount & access